Success spurs international expansion from North America to Europe and Latin America.
New era: CTI tapped for groundbreaking Stem Cell and Regenerative Medicine work.
Dozens of new trials launched including five ‘First-in-Human’ trials.
[CINCINNATI, Ohio ~ March 21, 2014] From the outside looking in, a “Contract Research Organization” (CRO) such as CTI Clinical Trial & Consulting Services is an organization providing support to the pharmaceutical, biotechnology, and medical-device industries.
But to the people touched by the efforts of CTI and its global force of staff researchers, physicians, nurses pharmacists and associated health care professionals, however, this privately-held, deeply passionate company and its people represent something so much more: specifically, life-changing therapies.
Celebrating its 15th year in 2013, the work performed by CTI throughout North America, Europe, and Latin America still attracts the biggest and the best, serving more than 70 large and mid-sized pharmaceutical and biotechnology companies, including eight of the 10 largest globally.International giants such as Astellas Pharma Inc. of Tokyo, Japan, formerly known as Fujisawa, and Genentech Roche of Switzerland have been clients since Day One.
CTI was founded by a Cincinnati native who’s a former University of Cincinnati Professor, Timothy J. Schroeder and Lynn Fallon, a former transplant nurse, administrator, and pharmaceutical executive.
The company’s niche mirrors the unique skills of its founders: combining expertise of clinical knowledge and market experience, CTI is uniquely positioned to incorporate both clinical and market-driven endpoints and interpretations to provide results.
CTI has worked on more than 1,200 projects, contributing to more than 30 new drug approvals working with the Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other global regulatory agencies.
CTI is an innovative, international drug and device development organization that delivers a full spectrum of clinical trial and consulting services from bench to commercialization with a focus on immunology and a passion for helping life-changing therapies succeed in chronically and critically ill patient populations.
The driving force for today’s internationally-focused CTI is a passion for the life-saving and life-changing opportunities afforded in the explosive areas of regenerative medicine and the stem cell marketplace.
Regenerative medicine presents enormous opportunity for mankind, and industry.
CTI helps clients navigate regulatory hurdles, and understands the complex logistics involved with conducting clinical research studies.
“Major advances are being made every day in diseases that are currently untreatable, and will continue to be made in the very near future,” said Schroeder, “and CTI will continue to play a significant role.”
While the future for CTI will encompass the company’s traditional sweet spots – clinical trial management, regulatory pathway design, data/market analysis including health economics, and consulting services – its focus is still on life-saving therapies, including regenerative medicine, specifically gene and stem cell therapies.
“Throughout my career, trends and science and technology are forever introducing us to new ideas, new ways for us to perform better, faster, with more meaningful results,” Schroeder said, “but nothing can touch what’s going on with stem cell therapies.
Despite its international reach, CTI is run like a family.
CTI works with the same Cincinnati-based bank, accounting firm, law firm, and printing company it had in 1999.
The firm is deeply dedicated to training, with employees logging at least 100 hours annually.
CTI has a 95 percent workforce retention rate, in 17 states and 15 countries. It’s currently looking to fill positions in North America, Europe, and Latin America.
Schroeder opened CTI in 1999 in a tiny office in Clifton, an uptown Cincinnati neighborhood, right down the street from his old employer, the University of Cincinnati.
As a Professor, Schroeder instructed on a wide range of subjects from health care and life sciences, often combining the two. The early years focused on North American work, and clients.
As the company’s reputation, network and bench strength grew – headquartered in Cincinnati (Blue Ash), with U.S. offices in Raleigh and Philadelphia, along with a string of European offices headquartered in Ulm, Germany – aforementioned work and client referrals transformed CTI into the innovative and international drug and device development organization it is today.
CTI’s focused therapeutic approach provides pharmaceutical, biotechnology and startup firms with clinical and disease area expertise from a unique mix of academic, medical and industry specialists; rich intellectual capital in transplantation, immunology, infectious diseases, hematology, cardiology, nephrology, hepatology, regenerative medicine and rare diseases; flexible study designs that accelerate development programs and deliver high approval ratings that are among the best in the industry; and exceptional global project management and gold standard safety and data management systems that strengthen their program’s success potential.
For more information, please visit www.CTIFacts.com.
# 30 #
Associate Manager, Marketing & Corporate Communications
10123 Alliance Road
Cincinnati, OH 45242